Opening the way to new treatments for lung disease.

Pulmokine, a biopharmaceutical company, develops innovative drug therapies and makes new pulmonary research solutions available to the R&D community.

Researching a new inhalable treatment for Pulmonary Arterial Hypertension (PAH).

We are in the pre-clinical phases of a new paradigm for the treatment of Pulmonary Arterial Hypertension (PAH), addressing the underlying causes of the disease.

PAH (Pulmomary Arterial Hypertension) – a pressing challenge.

There is a pressing unmet need for more effective treatments of Pulmonary Arterial Hypertension. A progressive disease caused by cell proliferation in lung blood vessels, PAH (high blood pressure in lung arteries) can adversely affect the heart.
More

A new class of drug: Our PDGFR kinase inhibitor technology.

We have developed a new class of inhalable drugs to decrease cell proliferation, instead of merely “relaxing” pulmonary arteries as today’s vasodilators do. Our hope after clinical trials is to prove greater efficacy with fewer side effects.
More

New discoveries made available for pulmonary research.

In solving the unique problems of our own pulmonary drug research, Pulmokine has developed patented inhalation systems and preclinical efficacy solutions that we are making available to the pulmonary drug development community.
More

Become a Pulmokine strategic partner
at the preclinical stage.

Pulmokine is interested in strategic partnerships with leading pharmaceutical corporations, R&D firms, licensors and/or investors to take our breakthrough technologies into the next phases of clinical development.

© 2013 Pulmokine. All Rights Reserved.

A pharmaceutical company developing new treatments for Pulmonary Hypertension.